John C. Chiu, M.D., has Agreed to be Medical Director and Chief Investigator of the Clinical Trials of Hyperdyne, Inc., a Subsidiary Being Created by Trimedyne, Inc.

LAKE FOREST, CA--(Marketwire - January 07, 2013) - TRIMEDYNE, INC. (“Trimedyne”) (OTCBB: TMED), today announced that John C. Chiu, M.D., an internationally respected neurosurgeon who practices in Newbury Park, CA, has agreed to serve as Medical Director and Chief Investigator of the three (3) randomized, controlled clinical trials to be conducted, subject to receiving funding, by Orthodyne, Inc., (“Orthodyne”), a subsidiary being a organized by Trimedyne.

John C. Chiu, M.D. is an internationally respected scientist and widely published neurosurgeon who specializes in Orthodyne’s minimally-invasive, outpatient procedures to treat pain arising from herniated or ruptured spinal discs, as well as pain arising from the facet, sacroiliac or vertebral joints of the spine. He has treated more than 10,000 patients using Trimedyne’s Holmium Lasers, Side Firing Needles and Optical Fiber Devices, and he is the author or co-author of more than 1,100 published papers, book chapters, scientific articles and presentations.

Dr. Chiu is the owner of the California Spine Institute, was a founder and is President or a past President of several medical societies for the minimally-invasive treatment of spinal conditions. He has received more than 100 Special Certifications and Academic Recognitions, been accorded more than 70 Honor Roll Awards, been a founder or member of 60 Professional Organizations, been honored by 26 Professional Appointments, and conducted more than 60 Educational and Training Seminars, a remarkable achievement for a neurosurgeon with a very busy neurosurgery and minimally-invasive spine surgery practice. Dr. Chiu’s Curriculum Vitae and accomplishments cover a total of 87 typewritten pages.

Trimedyne manufactures proprietary Holmium lasers and patented and patent pending fiber optic laser devices to treat a variety of medical conditions in minimally invasive, procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery. For product, press release, financial, SEC Reports and other information, please visit Trimedyne’s website, http://www.trimedyne.com.

“Safe Harbor” Statement Under the Private Securities Litigation Reform Act:

Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, including words like “believe,” “expect,” “may,” “could” and others. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company’s current Form 10-K Report and subsequently filed SEC Reports. There is no assurance such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in the statements in such Reports, which Trimedyne has no obligation to update.